This database contains 10 studies, archived under the term: "disease"
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, Vladimir,
Salloway, Stephen,
van Dyck, Christopher H.,
Dubois, Bruno,
Andreasen, Niels,
Brody, Mark,
Curtis, Craig,
Soininen, Hilkka,
Thein, Stephen,
Shiovitz, Thomas,
Pilcher, Gary,
Ferris, Steven,
Colby, Susan,
Kerselaers, Wendy,
Dockens, Randy,
Soares, Holly,
Kaplita, Stephen,
Luo, Feng,
Pachai, Chahin,
Bracoud, Luc,
Mintun, Mark,
Grill, Joshua D.,
Marek, Ken,
Seibyl, John,
Cedarbaum, Jesse M.,
Albright, Charles,
Feldman, Howard H.,
Berman, Robert M.
Importance: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild […]
Thyroid medication use and subsequent development of dementia of the Alzheimer type
Associations between medication use and the development of Alzheimer disease have been investigated since the late 1900s. Thyroid hormone supplementation is rarely a studied medication class in this area of research. We examined data from participants enrolled in longitudinal studies at the Washington University Alzheimer’s Disease Research Center for associations between thyroid disease, thyroid hormone […]
Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease
Zerr, I.,
Kallenberg, K.,
Summers, D. M.,
Romero, C.,
Taratuto, A.,
Heinemann, U.,
Breithaupt, M.,
Varges, D.,
Meissner, B.,
Ladogana, A.,
Schuur, M.,
Haik, S.,
Collins, S. J.,
Jansen, G. H.,
Stokin, G. B.,
Pimentel, J.,
Hewer, E.,
Collie, D.,
Smith, P.,
Roberts, H.,
Brandel, J. P.,
van Duijn, C.,
Pocchiari, M.,
Begue, C.,
Cras, P.,
Will, R. G.,
Sanchez-Juan, P.
Several molecular subtypes of sporadic Creutzfeldt-Jakob disease have been identified and electroencephalogram and cerebrospinal fluid biomarkers have been reported to support clinical diagnosis but with variable utility according to subtype. In recent years, a series of publications have demonstrated a potentially important role for magnetic resonance imaging in the pre-mortem diagnosis of sporadic Creutzfeldt-Jakob disease. […]
Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up
van den Bogaard, S. J. A.,
Dumas, E. M.,
Hart, E. P.,
Milles, J.,
Reilmann, R.,
Stout, J. C.,
Craufurd, D.,
Gibbard, C. R.,
Tabrizi, S. J.,
van Buchem, M. A.,
van der Grond, J.,
Roos, R. A. C.
Background and Purpose: MTI is a quantitative MR imaging technique that has recently demonstrated structural integrity differences between controls and patients with HD. Potentially, MTI can be used as a biomarker for monitoring disease progression. To establish the value of MTI as a biomarker, we aimed to examine the change in these measures during the […]
Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy
Miyoshi, F.,
Ogawa, T.,
Kitao, S.- i.,
Kitayama, M.,
Shinohara, Y.,
Takasugi, M.,
Fujii, S.,
Kaminou, T.
Background and Purpose: Progressive changes in the substantia nigra pars compacta and locus ceruleus of patients with Parkinson disease and Alzheimer disease visualized by neuromelanin MRI and cardiac postganglionic sympathetic nerve function on (123)I-metaiodobenzylguanidine scintigraphy have not been fully evaluated. We compared the diagnostic value of these modalities among patients with early Parkinson disease, late […]
Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study
Jackson, Graham S.,
Burk-Rafel, Jesse,
Edgeworth, Julie Ann,
Sicilia, Anita,
Abdilahi, Sabah,
Korteweg, Justine,
Mackey, Jonathan,
Thomas, Claire,
Wang, Guosu,
Schott, Jonathan M.,
Mummery, Catherine,
Chinnery, Patrick F.,
Mead, Simon,
Collinge, John
Importance: Our study indicates a prototype blood-based variant Creutzfeldt-Jakob disease (vCJD) assay has sufficient sensitivity and specificity to justify a large study comparing vCJD prevalence in the United Kingdom with a bovine spongiform encephalopathy-unexposed population. In a clinical diagnostic capacity, the assay’s likelihood ratios dramatically change an individual’s pretest disease odds to posttest probabilities and […]
Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial
Haïk, Stéphane,
Marcon, Gabriella,
Mallet, Alain,
Tettamanti, Mauro,
Welaratne, Arlette,
Giaccone, Giorgio,
Azimi, Shohreh,
Pietrini, Vladimiro,
Fabreguettes, Jean-Roch,
Imperiale, Daniele,
Cesaro, Pierre,
Buffa, Carlo,
Aucan, Christophe,
Lucca, Ugo,
Peckeu, Laurène,
Suardi, Silvia,
Tranchant, Christine,
Zerr, Inga,
Houillier, Caroline,
Redaelli, Veronica,
Vespignani, Hervé,
Campanella, Angela,
Sellal, François,
Krasnianski, Anna,
Seilhean, Danielle,
Heinemann, Uta,
Sedel, Frédéric,
Canovi, Mara,
Gobbi, Marco,
Di Fede, Giuseppe,
Laplanche, Jean-Louis,
Pocchiari, Maurizio,
Salmona, Mario,
Forloni, Gianluigi,
Brandel, Jean-Philippe,
Tagliavini, Fabrizio
Background: Creutzfeldt-Jakob disease (CJD) is a fatal, untreatable prion encephalopathy. Previous studies showed that doxycycline is effective in in-vitro and in-vivo models of disease, and patients with CJD who received compassionate treatment with doxycycline showed increased survival time compared with historical series. We therefore did a randomised, double-blind study of doxycycline versus placebo in CJD.; […]
Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease
Geschwind, M. D.,
Kuo, A. L.,
Wong, K. S.,
Haman, A.,
Devereux, G.,
Raudabaugh, B. J.,
Johnson, D. Y.,
Torres-Chae, C. C.,
Finley, R.,
Garcia, P.,
Thai, J. N.,
Cheng, H. Q.,
Neuhaus, J. M.,
Forner, S. A.,
Duncan, J. L.,
Possin, K. L.,
DeArmond, S. J.,
Prusiner, S. B.,
Miller, B. L.
Objective: To determine whether oral quinacrine increases survival in sporadic Creutzfeldt-Jakob disease (sCJD).; Methods: This NIH/National Institute on Aging-funded, double-blinded, placebo-controlled, stratified randomization treatment trial was conducted at the University of California, San Francisco from February 2005 through May 2009 (ClinicalTrials.gov, NCT00183092). Subjects were randomized (50:50) to quinacrine (300 mg daily) or placebo with inpatient […]
The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer’s disease
Bahl, Justyna Maria Czarna,
Heegaard, Niels H.H.,
Falkenhorst, Gerhard,
Laursen, Henning,
Høgenhaven, Hans,
Mølbak, Kåre,
Jespersgaard, Cathrine,
Hougs, Lotte,
Waldemar, Gunhild,
Johannsen, Peter,
Christiansen, Michael
Laboratory markers have a prominent place among the diagnostic criteria for sporadic Creutzfeldt-Jakob disease (sCJD). Here we investigate the capability of protein 14-3-3, total-tau (t-tau), threonin-181-phosphorylated tau (p-tau), and neuron-specific enolase (NSE) in cerebrospinal fluid (CSF) together with the prion protein gene genotype to discriminate patients with sCJD (n=21) from neurological controls (n=164) and Alzheimer’s […]
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies
Anderson, Craig,
Teo, Koon,
Gao, Peggy,
Arima, Hisatomi,
Dans, Antonio,
Unger, Thomas,
Commerford, Patrick,
Dyal, Leanne,
Schumacher, Helmut,
Pogue, Janice,
Paolasso, Ernesto,
Holwerda, Nicolaas,
Chazova, Irina,
Binbrek, Azan,
Young, James,
Yusuf, Salim
Background: cardiovascular risk factors are associated with dementia and cognitive decline. We investigated the effects of renin-angiotensin system blockade on cognitive function in patients aged 55 years and older with established atherosclerotic cardiovascular disease or diabetes with end-organ damage in two clinical trials.; Methods: in the main study, ONTARGET, a double-blind, double-dummy, randomised controlled trial, […]